These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29662199)

  • 1. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
    Gautam R; Nishimura Y; Gaughan N; Gazumyan A; Schoofs T; Buckler-White A; Seaman MS; Swihart BJ; Follmann DA; Nussenzweig MC; Martin MA
    Nat Med; 2018 May; 24(5):610-616. PubMed ID: 29662199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
    Gautam R; Nishimura Y; Pegu A; Nason MC; Klein F; Gazumyan A; Golijanin J; Buckler-White A; Sadjadpour R; Wang K; Mankoff Z; Schmidt SD; Lifson JD; Mascola JR; Nussenzweig MC; Martin MA
    Nature; 2016 May; 533(7601):105-109. PubMed ID: 27120156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus.
    Garber DA; Guenthner P; Mitchell J; Ellis S; Gazumyan A; Nason M; Seaman MS; McNicholl JM; Nussenzweig MC; Heneine W
    AIDS; 2021 Aug; 35(10):1567-1574. PubMed ID: 33966028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies.
    Garber DA; Adams DR; Guenthner P; Mitchell J; Kelley K; Schoofs T; Gazumyan A; Nason M; Seaman MS; McNicholl J; Nussenzweig MC; Heneine W
    Nat Commun; 2020 Jun; 11(1):3195. PubMed ID: 32581216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
    Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
    Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
    PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early antibody therapy can induce long-lasting immunity to SHIV.
    Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
    Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
    Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
    Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.
    Gardner MR; Kattenhorn LM; Kondur HR; von Schaewen M; Dorfman T; Chiang JJ; Haworth KG; Decker JM; Alpert MD; Bailey CC; Neale ES; Fellinger CH; Joshi VR; Fuchs SP; Martinez-Navio JM; Quinlan BD; Yao AY; Mouquet H; Gorman J; Zhang B; Poignard P; Nussenzweig MC; Burton DR; Kwong PD; Piatak M; Lifson JD; Gao G; Desrosiers RC; Evans DT; Hahn BH; Ploss A; Cannon PM; Seaman MS; Farzan M
    Nature; 2015 Mar; 519(7541):87-91. PubMed ID: 25707797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
    Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X
    PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
    Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
    EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
    Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
    Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
    Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
    Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
    J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
    Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF
    PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.